<DOC>
	<DOCNO>NCT01334268</DOCNO>
	<brief_summary>The primary objective study evaluate in-stent late lumen loss ( LLL ) 9 month , define difference post-procedure minimal lumen diameter ( MLD ) follow-up angiography MLD , Resolute Zotarolimus-Eluting Coronary Stent System compare Taxus Liberte Paclitaxel-Eluting Coronary Stent System real-world all-comer patient population require stent implantation .</brief_summary>
	<brief_title>Resolute Zotarolimus-Eluting Stent Versus Taxus Liberte Paclitaxel-Eluting Stent Percutaneous Coronary Intervention China</brief_title>
	<detailed_description>This study prospective , multicenter , randomize , two-arm , open-label study , design ass non-inferiority Resolute stent compare Taxus Liberte stent in-stent late lumen loss . The primary objective study evaluate in-stent late lumen loss ( LLL ) 9 month , define difference post-procedure minimal lumen diameter ( MLD ) follow-up angiography MLD , Resolute Zotarolimus-Eluting Coronary Stent System compare Taxus Liberte Paclitaxel-Eluting Coronary Stent System real-world all-comer patient population require stent implantation . This trial conduct approximately 20 site enroll 400 subject , randomize Resolute stent Taxus Liberte stent 1:1 ratio . Subjects randomize use interactive voice response system ( IVRS ) . Due design characteristic device , study investigator operator blind . However , clinical event adjudication committee , consist cardiologist participate study , blind treatment arm subject avoid potential bias adjudication process event .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patient must meet follow criterion eligible treatment trial : 1 . Age â‰¥ 18 year minimum age require local regulation 2 . The patient acceptable candidate treatment drugeluting stent accordance applicable guideline percutaneous coronary intervention , Instructions Use Resolute stent Taxus Liberte stent Declaration Helsinki 3 . The patient legal representative inform nature trial consent participate authorize collection release his/her medical information signing Patient Informed Consent Form 4 . Intention electively implant least one Resolute stent Taxus Liberte stent 5 . The patient willing able cooperate study procedure require follow visit Patients exclude trial follow criterion meet : 1 . Known intolerance aspirin , clopidogrel ticlopidin , heparin , bivalirudin , cobalt , nickel , chromium , molybdenum , 316L stainless steel , polymer coating ( e.g . Biolinx ) , zotarolimus , paclitaxel , rapamycin , tacrolimus , everolimus , analogue derivative , contrast medium 2 . Women know pregnancy lactate 3 . High probability nonadherence followup requirement ( due social , psychological medical reason ) 4 . Currently participate another trial complete primary endpoint clinically interfere current trial requirement 5 . Planned surgery within 6 month PCI unless dual antiplatelet therapy maintain throughout perisurgical period 6 . Previous enrollment Resolute China RCT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>In-stent Late Lumen Loss ( LLL )</keyword>
	<keyword>TARGET VESSEL FAILURE ( TVF )</keyword>
	<keyword>MYOCARDIAL INFARCTION ( MI )</keyword>
	<keyword>TARGET VESSEL REVASCULARIZATION ( TVR )</keyword>
	<keyword>TARGET LESION REVASCULARIZATION ( TLR )</keyword>
	<keyword>TARGET LESION FAILURE ( TLF )</keyword>
	<keyword>STENT THROMBOSIS</keyword>
	<keyword>RESTENOTIC LESION</keyword>
	<keyword>PERCUTANEOUS CORONARY INTERVENTION ( PCI )</keyword>
	<keyword>REAL-WORLD</keyword>
	<keyword>THE RANDOMIZED CONTROLLED TRIAL</keyword>
</DOC>